Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon

Antiviral Res. 1991 May;15(4):323-30. doi: 10.1016/0166-3542(91)90013-h.

Abstract

1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) has recently proved to be a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro. Combinations of HEPT and recombinant alpha interferon (IFN-alpha) synergistically inhibit the replication of HIV-1 in MT-4 cells at non-toxic concentrations. Synergistic inhibition of HIV-1 replication has also been observed in peripheral blood lymphocytes. These results indicate that the combination of HEPT with IFN-alpha should be further pursued in the treatment of retrovirus infections [i.e. acquired immune deficiency syndrome (AIDS)].

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / microbiology
  • Cells, Cultured
  • Cytopathogenic Effect, Viral
  • Drug Synergism
  • Drug Therapy, Combination
  • HIV-1 / drug effects*
  • HIV-1 / growth & development
  • HIV-1 / physiology
  • Humans
  • Interferon Type I / pharmacology*
  • Interferon Type I / therapeutic use
  • Recombinant Proteins
  • Thymine / analogs & derivatives*
  • Thymine / pharmacology
  • Thymine / therapeutic use
  • Virus Replication / drug effects*

Substances

  • Interferon Type I
  • Recombinant Proteins
  • 1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
  • Thymine